The drug, currently in a phase 1b/2 clinical trial for small cell lung cancer, is a polymer nanoparticle formulation of SN-38
OS is a key secondary endpoint of the 948-patient study, which is evaluating whether adding AstraZeneca's PD-L1 inhibitor to standard FLOT chemotherapy
New findings reveal bemarituzumab plus chemotherapy significantly improves survival in advanced gastric cancer, offering hope for targeted treatment options
Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
The launch is yet another first of its kind innovation in India
The findings, based on an exploratory analysis, indicate that CD47 expression may predict which patients benefit most from the therapy
CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
Adding one year of Imfinzi treatment to Bacillus Calmette-Guérin (BCG) induction and maintenance therapy delivered an early and sustained disease-free survival benefit vs. BCG alone
Subscribe To Our Newsletter & Stay Updated
